These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4560523)

  • 1. Controlled clinical trials denounced.
    Turkel H
    N Engl J Med; 1972 Oct; 287(16):826-7. PubMed ID: 4560523
    [No Abstract]   [Full Text] [Related]  

  • 2. Paediatric clinical trials: redressing the imbalance.
    Schreiner MS
    Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of effective new treatments for multiple myeloma.
    Anderson KC; Pazdur R; Farrell AT
    J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064
    [No Abstract]   [Full Text] [Related]  

  • 4. In brief: Non-inferiority trials.
    Med Lett Drugs Ther; 2011 Jan; 53(1355):1. PubMed ID: 21212743
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinically relevant end points and new drug approvals for myeloma.
    Anderson KC; Kyle RA; Rajkumar SV; Stewart AK; Weber D; Richardson P;
    Leukemia; 2008 Feb; 22(2):231-9. PubMed ID: 17972944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorides for multiple myeloma.
    Bierman HR
    N Engl J Med; 1972 Sep; 287(12):616-7. PubMed ID: 4560095
    [No Abstract]   [Full Text] [Related]  

  • 7. "Getting the dose right": facts, a blueprint, and encouragements.
    Peck CC; Cross JT
    Clin Pharmacol Ther; 2007 Jul; 82(1):12-4. PubMed ID: 17571068
    [No Abstract]   [Full Text] [Related]  

  • 8. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC; Farrell AT; Sridhara R; Pazdur R
    Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary for bortezomib for injection in the treatment of multiple myeloma.
    Bross PF; Kane R; Farrell AT; Abraham S; Benson K; Brower ME; Bradley S; Gobburu JV; Goheer A; Lee SL; Leighton J; Liang CY; Lostritto RT; McGuinn WD; Morse DE; Rahman A; Rosario LA; Verbois SL; Williams G; Wang YC; Pazdur R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3954-64. PubMed ID: 15217925
    [No Abstract]   [Full Text] [Related]  

  • 10. Pediatric drug studies. Protecting pint-sized patients.
    Nordenberg T
    FDA Consum; 1999; 33(3):23-8. PubMed ID: 10443186
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 12. Turning a blind eye.
    Nat Med; 2008 Jan; 14(1):1. PubMed ID: 18180702
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical, individualized dosing: 21st century therapeutics and the clinical pharmacometrician.
    Neely M; Jelliffe R
    J Clin Pharmacol; 2010 Jul; 50(7):842-7. PubMed ID: 20154293
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: Management of multiple myeloma.
    Yazici H
    N Engl J Med; 1976 Apr; 294(14):787-8. PubMed ID: 768763
    [No Abstract]   [Full Text] [Related]  

  • 15. A stepwise approach to evaluating new drug therapy.
    Wessell A; Blair M
    JAAPA; 2001 Nov; 14(11):10-1. PubMed ID: 11766421
    [No Abstract]   [Full Text] [Related]  

  • 16. Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.
    Wardell WM; Sheck LE
    Ration Drug Ther; 1983 Jan; 17(1):1-7. PubMed ID: 6340163
    [No Abstract]   [Full Text] [Related]  

  • 17. American Academy of Pediatrics. Committee on drugs. Drug testing in children: FDA regulations.
    Pediatrics; 1969 Mar; 43(3):463-5. PubMed ID: 5818481
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-marketing drug surveillance: an idea whose time has come.
    Strom BL
    Drug Ther; 1982; ():155-63. PubMed ID: 7105991
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's biomedical research program.
    Kelsey FO
    J Parenter Drug Assoc; 1980; 34(2):134-8. PubMed ID: 6989974
    [No Abstract]   [Full Text] [Related]  

  • 20. Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration.
    Feinsod M; Chambers WA
    Ophthalmology; 2004 Oct; 111(10):1801-6. PubMed ID: 15465539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.